Author: Matthew Nelson|| Date Published: August 7, 2020
An SRI International division has secured a potential seven-year, $100M contract to help a National Institutes of Health component develop methods to medical conditions caused by direct exposure or contamination from radioactive materials.
SRI Biosciences will support the National Institute of Allergy and Infectious Diseases in research and development of medical countermeasures for radiological and nuclear emergencies, the nonprofit said Wednesday.
The partnership will also explore biological dosimetry tests and advance candidate treatments for acute radiation syndromes, delayed effects from acute radiation exposure and internal radionuclide contamination.
Both NIH and NIAID have worked with SRI Biosciences to develop radiation therapies as part of a contract slated to expire this month.
Naval Information Warfare Center Atlantic has issued a solicitation seeking contractor support for shipboard command, control, communications, computers, cyber and intelligence,…
Radiance Technologies has elevated Darien Hammett to chief operating officer, placing him in charge of daily operations and execution across the company.…
latter’sRocket Lab announced Tuesday it has completed the acquisition of Mynaric, a laser-optical communications terminal provider, in a $155.3 million…
GreyNoise Intelligence has launched a command-and-control detection capability designed to give federal agencies earlier visibility into compromised infrastructure. GreyNoise’s new…
